If Nothing Else Changes.........and we know it already has with the addition of a rapid antigen test this is a company with a run rate of $60 million annually. The antigen tests cost $60 .....so selling only 20,000 of these a month creates a revenue stream that takes the company over $70 million this year.
It would seem Morningstar's Fair Value sp of $.15 is a far more reasonable valuation ....and that was before confirmation of sales this morning. Imho there is no logical reason for SCRN to be under $.20 ....and maybe even a little higher.
Hopefully this NR will put away any doubts about the capacity of the company to maintain their positive direction.
GLTE!!!